Trial Profile

A single and multiple dose-escalation first-in-human study evaluating the safety, tolerability, and pharmacokinetics of VS-041 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2025 According to a Vasa Therapeutics media release, Results of the study will be presented at upcoming scientific meetings.
04 Jun 2025 According to a Vasa Therapeutics media release, the company plan to advance development of VS-041 and test its effects on clinical and prognostic biomarkers of HFpEF, including endotrophin, in the target patient population later this year.
04 Jun 2025 Status changed from recruiting to completed, according to a Vasa Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com